A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

4 June, 2026

Report showcases a year of impactful research, collaboration and consumer engagement

LATEST NEWS: 4 June 2025 TROG’s latest Annual Research

ESTRO26 presentation
20 May, 2026

TROG trials in the spotlight at ESTRO26 international conference

LATEST NEWS: 20 MAY A number of TROG trials